Skip to main content

Medication-Assisted Treatment (MAT)

We're committed to supporting the complete care of patients with opioid use disorder (OUD) on their recovery journeys. Our MAT panels are designed to monitor patients on buprenorphine or buprenorphine/naloxone (e.g., Suboxone®, Subutex®, Zubsolv ®). We also offer panels suitable for methadone or naltrexone MAT.

What is medication-assisted treatment?

MAT is the use of medications in combination with counseling and behavioral therapies to treat OUD. Buprenorphine is one of the three drugs currently approved by the Food and Drug Administration (FDA) for the treatment of OUD.1

With Labcorp’s MAT drug testing portfolio—including three primary panels, individual drug class options and personal customization—you can support patients taking buprenorphine or buprenorphine/naloxone for MAT as they navigate the path to recovery.

NEW: MAT White Paper

We strive to provide exceptional customer service, patient care and consultative technical expertise

  • Extensive managed care network

  • Clinical drug testing support hotline: 877-474-5767

  • More than 2,000 patient service centers nationwide

  • Local courier services

  • Comprehensive EHR/EMR interfacing capabilities

Watch MAT Webinar

Your source for monitoring buprenorphine/naloxone treatment for OUD

Monitoring the norbuprenorphine-to-buprenorphine ratio over time can help confirm that your patient is taking their medication consistently as prescribed and detect urine spiking.

Labcorp MAT drug test options feature:

  • Optional enhanced reporting (by adding Test No. 702880), including summaries of patient medication compliance and cumulative testing results* 
  • Four-week sample retention for optimizing add-on testing opportunities 
  • Optimized detection thresholds for MAT patients
  • Norbuprenorphine to buprenorphine ratio for monitoring patient medication adherence over time*
  • Detection of naloxone in definitive tests for buprenorphine*
  • Enhanced specimen validity testing*
  • Compliance with SAMHSA 42 CFR Part 2 confidentiality regulation

*Not available as part of Test No. 705540

Watch our webinars

Webinar - 31 July 2024

How to interpret unexpected results due to patient metabolism or adulterated urine

Watch Webinar

Webinar - 31 July 2024

How to interpret unexpected negative or positive results

Watch Webinar

Webinar - 12 February 2024

Urine drug testing for medication-assisted treatment (MAT)

Watch Webinar

Webinar - 9 February 2024

Evolving drug trends and spotlight on xylazine

Watch Webinar

MAT screening options

NumberName
705540Drug Screen Only 18, Urine, Medication Assisted Treatment (MAT)
701957Buprenorphine MAT1, Urine, Medication Assisted Treatment (MAT)
701985Buprenorphine Medication Assisted Treatment Monitoring 2, Urine


Optional add-on testing

NumberName
705540Ketamine, MS Confirm, Urine, Medication Assisted Treatment (MAT)
702549

Kratom, Screen with Confirmation, Urine, Medication Assisted Treatment (MAT)

702550Methylphenidate, Screen With Confirmation, Urine, Medication Assisted Treatment (MAT)
702518Naltrexone, MS Confirm, Urine, Medication Assisted Treatment (MAT)
702551Nicotine Metabolite, Screen With Confirmation, Medication Assisted Treatment (MAT)


General health testing

Guideline-recommended baseline tests for OUD treatment2,3

Contact a sales representative to learn more about Labcorp's 
medication-assisted treatment portfolio. 
 

References:

  1. Food and Drug Administration (FDA). Information about Medication-Assisted Treatment (MAT). Accessed June 7, 2023. https://www.fda.gov/drugs/information-drug-class/information-about-medication-assisted-treatment-mat
  2. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004.
  3. The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update [published correction appears in J Addict Med. 2020 May/Jun;14(3):267]. J Addict Med. 2020;14(2S Suppl 1):1-91. doi:10.1097/ADM.0000000000000633.